Onco-Targets – Making loss of SFRP tumour suppressor function druggable
The invention discloses molecules, which are activated,
when function of Secreted Fizzled Related Protein 1 (SFRP1) is lost. SFRP1 is known to have tumour suppressor function and its loss is associated to tumour progression and poor survival. Access to the signalling pathways regulated by SFRP1 leads to novel targets for cancer therapy and diagnosis. Such druggable targets open the route to screening of small molecules and design of monoclonal antibodies, thereby enabling the development of innovative oncological treatments as well as new diagnostic markers.
Further Information: PDF
PROvendis GmbH
Phone: +49 (0)208/94105 10
Contact
Dipl.-Ing. Alfred Schillert
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Targeted use of enfortumab vedotin for the treatment of advanced urothelial carcinoma
New study identifies NECTIN4 amplification as a promising biomarker – Under the leadership of PD Dr. Niklas Klümper, Assistant Physician at the Department of Urology at the University Hospital Bonn…
A novel universal light-based technique
…to control valley polarization in bulk materials. An international team of researchers reports in Nature a new method that achieves valley polarization in centrosymmetric bulk materials in a non-material-specific way…
How evolution has optimised the magnetic sensor in birds
The magnetic sense of migratory birds is probably based on the protein cryptochrome 4, and a genetic study has now provided further support for this theory. A team of researchers…
